US009364520B2

(12) **United States Patent**
Pan et al.

(10) **Patent No.: US 9,364,520 B2**
(45) **Date of Patent: *Jun. 14, 2016**

(54) **FACTOR VIII CONJUGATES**

(75) Inventors: **Clark Q. Pan**, Castro Valley, CA (US); **John E. Murphy**, Berkeley, CA (US); **Baisong Mei**, Danville, CA (US); **Jonathan S. Strauss**, Walnut Creek, CA (US); **Hendri Tjandra**, Union City, CA (US); **Jianmin Chen**, Concord, CA (US); **Thomas Barnett**, Chapel Hill, NC (US); **Liang Tang**, Richmond, CA (US); **Deqian Wang**, Concord, CA (US)

(73) Assignee: **BAYER HEALTHCARE LLC**, Whippany, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1108 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/540,703**

(22) Filed: **Aug. 13, 2009**

(65) **Prior Publication Data**

US 2010/0081615 A1 Apr. 1, 2010

Related U.S. Application Data

(63) Continuation of application No. 11/273,896, filed on Nov. 14, 2005, now Pat. No. 7,632,921.

(60) Provisional application No. 60/627,277, filed on Nov. 12, 2004.

(51) **Int. Cl.**

A61K 38/37	(2006.01)
A61K 47/48	(2006.01)
C07K 14/755	(2006.01)
C07K 17/08	(2006.01)
A61K 38/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/37*** (2013.01); ***A61K 47/48215*** (2013.01); ***C07K 14/755*** (2013.01); ***C07K 17/08*** (2013.01); *A61K 38/00* (2013.01); *C07K 2319/00* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,970,300	A	11/1990	Fulton et al.
5,171,844	A	12/1992	van Ooyen et al.
5,422,260	A	6/1995	Kaufman et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	690126	1/1996
EP	786474 B1	7/1997

(Continued)

OTHER PUBLICATIONS

Brinkhous et al., Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs., Proc. Natl. Acad. Sci. USA, 1985, vol. 82, pp. 8752-8756.*

(Continued)

Primary Examiner — Alexander Kim

(74) *Attorney, Agent, or Firm* — Buchanan, Ingersoll & Rooney

(57) **ABSTRACT**

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

9 Claims, 38 Drawing Sheets